503A vs 503B vs RUO: The Three US Peptide Supply Chains, Compared

• ·Peptides reach US users through three legally distinct channels: 503A compounding pharmacies, 503B outsourcing facilities, and research-use-only (RUO) reagent suppliers.
• ·503A and 503B produce drugs for patients. RUO suppliers sell chemical reagents for laboratory research and may not market them for human use.[1]
• ·Each channel has different quality obligations. 503B facilities follow current good manufacturing practice (CGMP). RUO quality depends on the supplier, which is why independent batch testing matters.[2]

Section 503A of the Federal Food, Drug, and Cosmetic Act exempts drugs compounded by a licensed pharmacist or physician from the Act's requirements on FDA approval, CGMP and labeling with adequate directions for use, provided the drug is compounded for an individual patient on a valid patient-specific prescription.[2] Key constraints:

• ·Ingredients. Bulk drug substances must have a USP or NF monograph, be a component of an FDA-approved drug, or appear on the 503A bulks list. This is why the July 2026 PCAC votes on BPC-157 and other peptides mattered to pharmacies.[3]
• ·Oversight. Primarily state boards of pharmacy, with FDA authority for certain violations.[3]
• ·Quality standard. USP compounding chapters (for example, USP <797> for sterile preparations) rather than full CGMP, from which 503A compounding is exempt.[2]

Research Material

Section 503B, created by the Drug Quality and Security Act of 2013, lets a compounder register with the FDA as an outsourcing facility and compound in larger batches, distributing either on patient-specific prescriptions or on orders from health care providers such as hospitals.[2] Key constraints:

• ·Ingredients. Bulk drug substances must be on the 503B bulks list, which covers substances with a clinical need, or the drug made from them must be on the FDA's drug shortage list at the time of compounding, distribution and dispensing.[4]
• ·Oversight. Direct FDA registration, risk-based FDA inspection, and adverse-event reporting.[2]
• ·Quality standard. CGMP, the same framework that applies to drug manufacturers.[2]
• ·Why it mattered for the GLP-1 class. During the semaglutide and tirzepatide shortages, compounders, outsourcing facilities included, could make those drugs. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage in February 2025, and the transition periods for outsourcing facilities ended in March and May 2025 respectively.[5]

A research reagent supplier is not a pharmacy and not a drug manufacturer. It sells chemicals for in vitro and laboratory research. The governing question is intended use: if the product is marketed, labeled or distributed in a way that shows it is intended for human use, the FDA treats it as an unapproved drug.[1] Key features:

• ·Ingredients. No bulks list applies, because the product is not a drug. Investigational compounds such as retatrutide can be supplied for research, provided nothing suggests human use.
• ·Oversight. The FDA acts through warning letters, import alerts and enforcement when marketing crosses into drug claims. Our post on what research use only means after the 2026 warning letters covers what triggers action.
• ·Quality standard. None is mandated. Quality is whatever the supplier can demonstrate.

Amino Acid Sequence

Chemical Structure

• ·What the product legally is. 503A pharmacy: a compounded drug. 503B outsourcing facility: a compounded drug. RUO supplier: a research reagent.
• ·End user. 503A: an individual patient. 503B: patients, via providers. RUO: laboratories.
• ·Prescription. 503A: required. 503B: not always. RUO: not applicable.
• ·Federal registration. 503A: no (state-licensed). 503B: yes, with the FDA. RUO: no.
• ·Quality framework. 503A: USP compounding chapters. 503B: CGMP. RUO: supplier-defined.
• ·Ingredient rules. 503A: the 503A bulks list, a monograph, or an approved-drug component. 503B: the 503B bulks list or the shortage list. RUO: none, because the product is not a drug.
• ·Human use. 503A: for the prescribed patient. 503B: for patients, via providers. RUO: not permitted, and marketing toward it is what turns a reagent into an unapproved drug.

Because no federal standard defines RUO peptide quality, two vials with the same label can differ widely in identity, purity, peptide content and endotoxin load. For research, that is a reproducibility problem: an experiment run on a 92%-pure lot with an unknown impurity is not comparable to one run on a 99%-pure lot.

Labs can close that gap by requiring the four things below. Eppix Labs publishes a batch-specific third-party certificate for every lot on its certificates of analysis page, with purity and measured content as the laboratory reported them, and adds endotoxin results for the lots picked for random screening. The current retatrutide certificate is shown after the list.

• ·Batch-specific third-party certificates, not a single generic certificate reused across lots. See how to read a Janoshik COA.
• ·Mass confirmation of identity, not only HPLC purity.
• ·Measured content against the label claim. Our post on HPLC purity vs net peptide content explains why these differ.
• ·Endotoxin data where the research model is sensitive to it. See our endotoxin testing guide.

Published Certificate

Select strength

10mg20mg40mg50mg

Batch

RETA-CA-26E-01

Purity (HPLC)

99.637%

Measured content

11.76 mglabeled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

Available at Eppix Labs

Retatrutide (Triple Agonist)

10mg · 20mg · 40mg · 50mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $79.99 USDIn stock